Becton Dickinson and Company (BDX): $7.29 million was the positive money flow into the stock on Friday and the up/down ratio of ticks was also in favor of the bulls at 1.3. The value of trades done on upticks was $31.82 million, whereas, trades done on downticks were valued at $24.53 million. Money flows are calculated as the dollar value of composite uptick trades minus the dollar value of downtick trades. large traders, also sometimes called as the smart money, block traded $10.66 million worth stocks on upticks, which is a bullish indication. The money flow in block trades was $10.66 million. Becton Dickinson and Company (BDX) fell $1.19 traded at $173.67, a change of -0.68% over the previous day. The stock is -0.81% for the week.
Becton Dickinson and Company (BDX) has been rated by 11 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $200 and the lowest price target forecast is $169. The average forecast of all the analysts is $183.46 and the expected standard deviation is $9.08.
Becton Dickinson and Company (NYSE:BDX): On Fridays trading session , Opening price of the stock was $174.65 with an intraday high of $174.73. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $172.02. However, the stock managed to close at $173.67, a loss of 0.68% for the day. On the previous day, the stock had closed at $174.86. The total traded volume of the day was 638,856 shares.
In a related news, The Securities and Exchange Commission has divulged that Gallagher John E, officer (VP, Corp Finance and Treasurer) of Becton Dickinson & Co, had unloaded 1,931 shares at an average price of $169.87 in a transaction dated on June 13, 2016. The total value of the transaction was worth $328,019.
Becton, Dickinson and Company is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, life science researchers, clinical laboratories, pharmaceutical industry and the general public. The Company operates through two segments: BD Medical and BD Life Sciences. The Companys Life Sciences segment consists of the BD Diagnostics and BD Biosciences segments. The Companys BD Medical segment focuses on providing solutions to reduce the spread of infection, enhance diabetes treatment and advance drug delivery. The Companys BD Diagnostics provides products for the safe collection and transport of diagnostics specimens, as well as instruments and reagent systems. Its BD Biosciences provide diagnostic and research tools to life science researchers, clinical researchers, laboratory professionals and clinicians.